Nektar Therapeutics (NKTR) Reports Q4 Loss, Lags Revenue Estimates
28/2 23:35
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $0.65 per share a year ago. These figures are adjusted for non-recurring items....